Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics Inc (NQ: ALLO )

3.080 -0.110 (-3.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Allogene Therapeutics's Return On Capital Employed Insights
Via Benzinga
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
Via Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
5 Analysts Have This to Say About Allogene Therapeutics
Via Benzinga
Expert Ratings for Allogene Therapeutics
Via Benzinga
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Short Squeezes Have Returned in 2023 -- Here's Your Playbook
We haven't seen moves like these in a couple of years, so here's what investors should know. 
Via The Motley Fool
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
Allogene Therapeutics Inc (NASDAQ: ALLO) shares are trading higher by 13.1% to $7.76 Tuesday morning after the company announced data from its Phase 1 UNIVERSAL trial of ALLO-715 has been published in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
Via Benzinga
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Amazon To Rally Over 28%? Here Are 10 Other Analyst Forecasts For Tuesday
Citigroup raised the price target for AT&T Inc. (NYSE: T) from $20 to $22. Citigroup analyst Michael Rollins maintained a Buy rating. AT&T shares fell 1% to $18.91 in pre-market trading. 
Via Benzinga
Yext, 1-800-Flowers.com And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
WWE, AMTD Digital And Some Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. AMTD Digital Inc. (NYSE: HKD) shares surged 118.8% to $65.54 in pre-market... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 63 companies set new 52-week lows. 
Via Benzinga
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
Top 10 Highest Short Interest Stocks And 10 With Highest Cost To Borrow: Where Do Carvana, MicroStrategy, Fisker And AMC Rank?
Investors often look for stocks with high short interest and a high cost to borrow, which could predict a potential short squeeze. New data shared by S3 Partners could signal which stocks investors are... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
-Clinical Data Due Next Week at ASH- 
Via Benzinga
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
From Allogene Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.